<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342170</url>
  </required_header>
  <id_info>
    <org_study_id>ABOCIRRALVIR</org_study_id>
    <nct_id>NCT03342170</nct_id>
  </id_info>
  <brief_title>Influence of ABO Blood Group on the Risk of Complications in Alcoholic or Viral C Cirrhosis?</brief_title>
  <acronym>ABOCIRRALVIR</acronym>
  <official_title>Influence of ABO Blood Group on the Risk of Complications in Alcoholic or Viral C Cirrhosis? Analysis From Two French Prospectives National Cohorts CIRRAL and CIRVIR of Patients With Alcoholic or Viral Cirrhosis Child Pugh A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thong DAO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Annie BOREL-DERLON</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nathalie GANNE-CARRIE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre NAHON</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sylvie CHEVRET</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The non-O blood group is a risk factor of deep vein thrombosis and recurrence of
      thromboembolic events, especially when associated with Factor 5 Leiden or prothrombin G20210A
      mutations. A recent study suggests that non-O blood group may promote portal vein thrombosis
      in non cirrhotic patients.

      In addition, in general population and chronic hepatitis C, non-O blood group combined with
      one or the other of the above genetic abnormalities is associated with an increased risk of
      liver fibrosis and accelerated fibrogenesis. The suspected mechanism could be an increased
      procoagulant factor VIII and an increased Willebrand plasma level, due to a low ADAMTS 13
      activity, the result of which is an hypercoagulable state and a microthrombotic process.

      In cirrhotic patients procoagulant factors and ADAMTS 13 which are respectively increased and
      decreased, have be shown to be prognostic markers of hepatocellular function and portal
      hypertension. It has been hypothesized that the hypercoagulable state and the microthrombotic
      process could contribute to the worsening of the disease and enoxaparin has been shown to
      positively modify the prognosis of cirrhosis.

      The role of non-O blood group in decompensation of cirrhosis and occurrence of complications
      including non-tumor portal vein thrombosis has never been studied. The investigators plan a
      longitudinal observational study to determine the incidence of complications in alcoholic and
      viral cirrhosis in case of non-O blood group compared to O blood group. The aim of this study
      is to determine whether ABO blood group may promote complications in alcoholic or viral
      cirrhosis. This is an ancillary study of two national cohorts assessing natural history and
      hepatocellular carcinoma risk factors in alcoholic (CIRRAL) and viral (CIRVIR) cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>cumulated incidence of complications at 3 years</measure>
    <time_frame>from inclusion to 3 years</time_frame>
    <description>patient follow up during 3 years</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Alcoholic or Viral C Compensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>CIRRAL</arm_group_label>
    <description>alcoholic cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIRVIR</arm_group_label>
    <description>Viral cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>G20210A prothrombin gene mutation and Factor 5 Leiden mutation</intervention_name>
    <description>blood sample</description>
    <arm_group_label>CIRRAL</arm_group_label>
    <arm_group_label>CIRVIR</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      G20210A prothrombin gene mutation Factor 5 Leiden mutation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        cohorts of cirrhotics patients Child Pugh A followed prospectively to study the natural
        history of cirrhosis and HCC risk
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with either alcoholic or viral C cirrhosis included in national cohorts CIRRAL
             and CIRVIR

        Exclusion Criteria:

          -  Those of CIRRAL and CIRVIR with None Tumoral Portal Thrombosis prior history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle OLLIVIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume DELAVAL</last_name>
    <phone>+33 2 31 06 54 32</phone>
    <email>delaval-g@chu-caen.fr</email>
  </overall_contact>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

